Last updated: April 11, 2023
Sponsor: Photolitec LLC
Overall Status: Active - Recruiting
Phase
1
Condition
Glioblastoma Multiforme
Gliomas
Astrocytoma
Treatment
N/AClinical Study ID
NCT05363826
14598
4R44CA247127-02
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥ 18years.
- Subject has a Karnofsky performance status ≥ 70 (i.e. the subject must be able to carefor himself/herself with occasional help from others; refer to Appendix G).
- Subject has pathologically confirmed diagnosis of glioblastoma or gliosarcoma.
- Subject has recurrent or progressive tumor following standard therapy.
- Subject has recurrent cerebral tumor that in the opinion of the treating neurosurgeonis surgically resectable.
- Subject has the following clinical laboratory values obtained within 14 days prior toregistration: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L Hemoglobin (Hgb) > 9.0 g/dL Plasma total bilirubin: ≤ 1.5x ULN ALT and AST ≤ 2.0 x ULN Creatinine clearance >60 WBC ≥ 4000 INR ≤ 1.1 x ULN
- Subject will have been off all anticoagulant therapy (e.g., warfarin, heparin,enoxaparin, rivaroxaban, apixaban, aspirin) for at least 5 days before surgery andPhotobac® infusion.
- No active bleeding or pathological condition that in the judgement of the principalinvestigator carries a high risk of bleeding
- Subject of child-bearing potential "agrees to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entryand have a negative pregnancy test prior to starting study treatment. Should a womanbecome pregnant or suspect she is pregnant while she or her partner is participatingin this study, she should inform her treating physician immediately.
- Subject has completed radiation therapy (RT) and temozolomide (TMZ) for the treatmentof their glioblastoma or gliosarcoma at least 30 days prior to entry
- Participant must understand the investigational nature of this study and sign anIndependent Ethics Committee/Institutional Review Board approved written informedconsent form prior to receiving any study related procedure.
Exclusion
Exclusion Criteria:
- Subject has serious concurrent infection or medical illness, which in the treatingphysician's opinion would jeopardize the ability of the subject to receive thetreatment outlined in this protocol with reasonable safety.
- Subject is pregnant or breast-feeding.
- Subject has latex allergy.
- Subject has received another chemotherapeutic or investigational agent in addition toradiation therapy and concomitant temozolomide treatment within 30 days of plannedPDT.
- Subject has persistent toxicity of prior therapy.
- Subject has gliomatosis cerebri.
- Subject has cerebral tumor that in the opinion of the treating neurosurgeon isunresectable.
- Subject has brainstem, spinal cord or cerebellar involvement by tumor.
- Subject has known human immunodeficiency virus (HIV) positivity or acquiredimmunodeficiency syndrome (AIDS) related illness or other serious medical illness.
- Subject has contraindication to MRI scans or gadolinium contrast agent.
- Subject has history of porphyria, hypersensitivity to porphyrin or porphyrin-likecompounds or any other abnormal skin photosensitivity.
- Subject is unwilling or unable to follow protocol requirements.
- Subject has any condition which in the Investigator's opinion makes the subjectunsuitable to receive the study drug. Must be reported.
- Subject has any condition which in the treating neurosurgeon's opinion makes thesubject unsuitable to undergo craniotomy for tumor resection.
- Subject has received an investigational agent within 30 days prior to planned PDT.
- Subject has midline shift > 1 cm.
- Subject is unable to give consent to participate in the study.
- Subject has a QTC interval > 470 milliseconds (CTCAE grade 1) using Frederica's QTcorrection formula.
- Subject has serious concurrent infection or medical illness, which in the treatingphysician's opinion would jeopardize the ability of the subject to tolerate the addedhour o anesthesia outlined in this protocol with reasonable safety.
Study Design
Total Participants: 30
Study Start date:
April 11, 2023
Estimated Completion Date:
May 31, 2026
Study Description
Connect with a study center
Roswell Park Cancer
Buffalo, New York 14263
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.